Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
β-Agonists and asthma: too much of a good thing?
Stephanie A. Shore, Jeffrey M. Drazen
Stephanie A. Shore, Jeffrey M. Drazen
Published August 15, 2003
Citation Information: J Clin Invest. 2003;112(4):495-497. https://doi.org/10.1172/JCI19642.
View: Text | PDF
Commentary

β-Agonists and asthma: too much of a good thing?

  • Text
  • PDF
Abstract

In an unusual paradox, asthmatics who are chronically treated with bronchodilating β-agonists sometimes experience a worsening of their condition. A new study describes one possible mechanism and reveals a potential new therapeutic target in the treatment of asthma.

Authors

Stephanie A. Shore, Jeffrey M. Drazen

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
(a) Mechanism of β-agonist–induced airway smooth muscle relaxation. Liga...
(a) Mechanism of β-agonist–induced airway smooth muscle relaxation. Ligand binding to the β2AR activates Gs, leading to adenylyl cyclase (AC) activation, cAMP formation, and subsequent protein kinase A (PKA) activation. PKA phosphorylation of target proteins leads to smooth muscle relaxation and may also inhibit ERK activation. PKA also phosphorylates the β2AR, leading to increased Gi coupling. In addition, ligand binding causes G protein receptor kinase (GRK) phosphorylation of the β2AR, recruiting β-arrestin (ARR). (b) Inflammatory events in the asthmatic airway or regular β-agonist use may augment Gi coupling and/or increase β-arrestin binding. Under these circumstances, β-agonists may result in ERK activation, potentially amplifying production of inflammatory cytokines and leading to airway remodeling. Persistent activation of the β2AR may also lead to phospholipase C-β (PLCβ) expression and consequent airway hyperresponsiveness (8).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts